STOCK TITAN

Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) has announced a presentation by CEO N. Scott Fine at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 PM ET. The event includes a live video webcast and opportunities for virtual one-on-one meetings with investors.

The company is focused on developing treatments for rare diseases, particularly Niemann-Pick Disease Type C, with its Trappsol® Cyclo™ drug currently undergoing multiple clinical trials.

Positive
  • None.
Negative
  • None.

Presentation with live video webcast on Wednesday, March 16th at 3:20 PM ET

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 PM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the virtual event will be available on the Events page of the Investors section of the Company’s website (cyclotherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

JTC Team, LLC

Jenene Thomas

(833) 475-8247

CYTH@jtcir.com

Source: Cyclo Therapeutics, Inc.

FAQ

When is Cyclo Therapeutics' presentation at the Oppenheimer Conference?

Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 PM ET.

Who is presenting for Cyclo Therapeutics at the conference?

N. Scott Fine, the CEO of Cyclo Therapeutics, will present at the conference.

Where can I watch the Cyclo Therapeutics presentation?

The presentation will be available via a live video webcast on the Events page of Cyclo Therapeutics' website.

What is Trappsol® Cyclo™ being developed for?

Trappsol® Cyclo™ is being developed for Niemann-Pick Disease Type C and is also being explored for Alzheimer's Disease.

How many clinical trials is Cyclo Therapeutics conducting?

Cyclo Therapeutics is conducting four formal clinical trials for Niemann-Pick Disease Type C.

What is the stock symbol for Cyclo Therapeutics?

The stock symbol for Cyclo Therapeutics is CYTH.

Cyclo Therapeutics, Inc.

NASDAQ:CYTH

CYTH Rankings

CYTH Latest News

CYTH Stock Data

18.08M
17.10M
40.08%
13.17%
0.4%
Drug Manufacturers - Specialty & Generic
Biological Products, (no Disgnostic Substances)
Link
United States of America
GAINESVILLE